



Proteomics International

LABORATORIES LTD

ASX Release

18 March 2024

ASX code: PIQ

Update on commercialisation of PromarkerD in the USA and commercial development of the Promarker diagnostics pipeline

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) continues to work diligently toward a national launch in the United States of America, of PromarkerD, the Company's innovative predictive test for diabetic kidney disease, and also advancing the development of its rich pipeline of diagnostic tests for other chronic diseases.

Proteomics International advises that, based on its latest assessment of the necessary technical and commercial work required to launch PromarkerD in the USA, the USA launch previously planned for Q2 2024, is now likely to be delayed.

The work required to launch a novel test has multiple components and, whilst considerable progress has been made preparing PromarkerD for the US market, the complexities involved in bringing a new test into broad clinical use have meant the process is taking longer than expected.

The Company continues to engage with its USA licensee, Sonic Healthcare USA [ASX: 10 May 2023] and will provide further updates to the market, as and when information becomes available.

Significantly, our experience with PromarkerD has provided the Company with invaluable knowledge and experience to accelerate the commercialisation of other tests in development. To this end, the necessary technical work has already commenced to prepare for the commercialisation of PromarkerEndo, the Company's test for endometriosis, and PromarkerEso, the Company's test for oesophageal cancer.

The Company remains focussed on executing further licensing and distribution deals in new jurisdictions for its PromarkerD test and is currently in discussions with a number of parties.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

About PromarkerD (www.PromarkerD.com)

Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique 'fingerprint' of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDLcholesterol and estimated glomerular filtration rate (eGFR)). A cloud-based algorithm integrates the results into a patient risk report. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years. Further information is available through the PromarkerD web portal.

About the Promarker™ Platform

Proteomics International's diagnostics development is made possible by the Company's proprietary biomarker discovery platform called Promarker, which searches for protein 'fingerprints' in a sample. This disruptive technology can identify proteins that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful alternative to genetic testing. The technology is so versatile it can be used to identify fingerprints from any biological source, from wheat seeds to human serum. The Promarker platform was previously used to develop PromarkerD, a world-first predictive test for diabetic kidney disease, that is currently being commercialised. Other tests in development include for endometriosis, asthma & COPD, oesophageal cancer, diabetic retinopathy and oxidative stress.

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Lisa Barnes
Public Relations
Profile Media
T: +61 416 583 672
E: lisab@profilemedia.com.au

Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com